Key clinical point: Deescalating 6-month rituximab dosage from 1,000 mg to 500 mg in MS patients is safe and results in clinical stability.
Major finding: No significant differences were observed when comparing Expanded Disability Status Scale scores at the start of the 1,000-mg dose with the start of the 500-mg dose (Wilcoxon P = .131).
Study details: A prospective, observational, single-center study of 59 patients with multiple sclerosis who were on 1,000 mg of rituximab for at least 1 year.
Disclosures: The study was supported by the Neurocenter of Southern Switzerland. One author declared numerous potential conflicts of interest, including receiving speaker fees, research fees, and travel support, and serving on advisory boards for various foundations, universities, and pharmaceutical companies.
Disanto G et al. Mult Scler J. 2020 Aug 25. doi: 10.1177/1352458520952036.